Document is current
Any future updates will be listed below
-
Authors
Rensink, Max J. https://orcid.org/0000-0003-4799-8587
Schermer, M. H. N.
Tibben, A.
Bijlsma, E. K.
de Bot, S. T.
Kievit, J. A.
Bolt, L. L. E.
-
Funding
Funding for this research was provided by:
Nederlandse Organisatie voor Wetenschappelijk Onderzoek (NWA.1389.20.244)
- License Information
-
More Information
Article History
Received: 2 September 2024
Accepted: 5 May 2025
First Online: 26 May 2025
Declarations
:
: Susanne T. de Bot: Leiden University Medical Centre received grants from the European Huntington’s Disease Network (EHDN) and Cure HD Initiative (CHDI), participates in an EU Horizon 2020 project: Innovative Medicines Initiative (IMI) 2 (IDEA_FAST), and participates in clinical trials sponsored by PRILENIA, PTC Therapeutics, WAVE and VICO Therapeutics. Susanne T. de Bot is member of the HD Expert Advisory Panel for the PTC518 phase 3 program (PTC Therapeutics). The aforementioned sponsors had no role in the design, execution, interpretation, or writing of this current study. The other authors declare no conflict of interest.
